Mr. Kaiser serves as Evecxia’s Chief Executive Officer (CEO) and interim Chairman of the Board of Directors. Prior to Evecxia, he was interim CEO of Cerecor, Inc., a public, CNS focused biopharmaceutical company located in Baltimore, MD. Mr. Kaiser also held the title of Chief Business Officer with responsibilities for corporate strategy, strategic marketing and business development and led the company to acquire both CERC-301 & CERC-406 from Merck in 2013, CERC-501 in 2015 and CERC-611 in 2016, both from Lilly respectively. He also led the company’s efforts to divest of CERC-501, selling the asset to Johnson & Johnson in 2017.
Prior to joining Cerecor, Mr. Kaiser founded Denysias Bioscience, LLC, a biopharmaceutical company focused on developing new therapies for neuropsychiatric disorders, where he served as CEO. At the same time, Mr. Kaiser also served as President of Kaiser & Associates Consulting, a boutique consulting firm providing strategic corporate and commercial expertise to the biopharmaceutical industry. From 2008-2009, Mr. Kaiser served as Vice President of Commercial and Business Development at ACADIA Pharmaceuticals Inc.
Before ACADIA, Mr. Kaiser held numerous positions of increasing responsibilities at Eli Lilly and Company for more than 25 years. At Lilly, Mr. Kaiser held various assignments of increasing responsibilities in sales, marketing and general management in the US and the European theater. At Lilly, Mr. Kaiser led the global commercialization efforts of Prozac®, the global strategic marketing efforts for Cymbalta®, and helped drive the commercial success of Zyprexa® internationally. Mr. Kaiser also led the strategic marketing efforts for the company’s CNS development portfolio and co-led the development and execution of the company’s CNS strategy.
Mr. Kaiser leads Evecxia’s Senior Management Team and Board of Directors, and currently serves on the Board of Directors of NH Therapeutics. Mr. Kaiser received his B.S. in pharmaceutical sciences from the James L. Winkle College of Pharmacy at the University of Cincinnati.
Dr. Jacobsen serves as Evecxia’s Chief Scientific Officer. Dr. Jacobsen is the inventor of the 5-hydroxytryptophan slow-release (5-HTP SR) therapeutic concept. Prior to Evecxia, he served in various scientist roles at Duke University and Duke-National University Singapore, from 2008-2018. In these capacities, Dr. Jacobsen has been the main driver on a cross-disciplinary team executing the seminal work on the 5-HTP SR therapeutic concept, including building the clinical concept, preclinical proof-of-concept, intellectual property, and regulatory affairs.
Prior, Dr. Jacobsen spend 8 years in pharma-biotech, at Neurosearch and at Lundbeck. Here, he executed a variety of projects within the realms of drug discovery and target validation.
Dr. Jacobsen has published multiple scientific papers, including in the highest ranked in the field of Psychiatry. He is the inventor on several patents pertaining to the 5-HTP SR therapeutic concept. He holds a PhD in neuropharmacology from the University of Copenhagen.
Dr. Beasley trained as a Psychiatrist and has over 30 years of CNS drug development experience from Eli Lilly. He retired from Lilly in 2015 as Distinguished Lilly Scholar (Vice-Presidential level).
Dr. Beasley has executive level experience in the design, conduct, analysis, and successful submission of multiple Psychiatry Phase II-IV development programs. Additional work with select Phase I studies in various areas especially cardiac electrophysiology assessment. Extensive experience in the domain of drug safety evaluation in response to high-profile challenges to the safety profiles of several drugs. Published widely in the scientific literature while in industry, gaining the respect of the academic community as exemplified by being elected to the highly competitive and prestigious American College of Neuropsychopharmacology. Training and research in computer science and statistics facilitate accurate and efficient collaboration with data scientists and statisticians, enhancing quality in progressing from study protocols to submissions and scientific manuscripts.
Mr. Piskorski has over 40 years’ experience in pharmaceuticals and medical devices, with particular expertise in all aspects of commercializing new drug products and technologies. He was COO at Euthymics/Neurovance, a Cambridge startup developing triple reuptake inhibitor drugs for different psychiatric disorder. Neurovance was recently acquired by Otsuka Pharmaceuticals in March 2017.
As SVP Technical Operations at Orexigen Therapeutics, he directed all CMC and Quality activities as well as clinical supply operations, resulting in a successful NDA submission and eventual drug approval for Contrave, a combination of buproprion/naltrexone for weight. During his 12 years at Sepracor, now Sunovion, he launched four new NDA products, all of different dosage forms and manufacturing technologies. The extremely successful launch of Lunesta was characterized by Forbes magazine as the “5thbest launch in pharma history”. He grew the outsourced operations from zero to a level supporting $1.2B of sales.
Prior to Sepracor he managed the development of various respiratory pMDI drugs at Armstrong Pharmaceuticals. There he led the team that successfully obtained the first generic albuterol pMDI inhaler ANDA for a US company. Earlier in his career at C.R.Bard, Baxter International and Bristol Myers, Mr. Piskorski held various positions that built a wealth of diverse product and technology know-how. He successfully bridges the different technical/clinical skills needed to commercialize new drugs. His techno/business expertise spans a wide range of drug products ranging from Class IV, high potency, controlled substances to generic pressurized Meter Dose Inhalers (pMDI). In addition to designing pharmaceutical production facilities, he has managed the preparation of various types of regulatory submissions: 510(k), ANDA and NDA. Mr. Piskorski has a degree in Chemical Engineering from Rensselaer Polytechnic Institute, a MBA from Syracuse Univ. and did post-graduate studies in Operations Research.